Adaptimmune Therapeutics plc(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer opened its new UK headquarters in Milton Park, Oxfordshire.
Over 400 people, including employees and senior representatives from the regional and national business, academic, government and investor communities, will gathered to celebrate the official opening of the flagship facility. Professor Sir John Bell GBE, FRS, Regius Professor of Medicine at the University of Oxford, unveiled a commemorative plaque.
Adaptimmune’s state-of-the-art 67,000 square foot building comprises laboratory and office space and is designed to accommodate all of the Company’s U.K. research and development operations and corporate teams. This facility at Milton Park, Oxfordshire, complements Adaptimmune’s newly built U.S. headquarters and clinical and manufacturing operations at the Navy Yard in Philadelphia, PA.
“We are proud to celebrate the official opening of this exciting new building, which provides best-in-class laboratories to support the activity of our highly skilled research and development teams and the advancement of our research programs,” said James Noble, Chief Executive Officer of Adaptimmune. “We started up Adaptimmune with three people in a small laboratory on Milton Park in 2008 to conduct research into engineered T-cell receptors to fight cancer and we now have more than 350 staff working out of our U.K. and U.S. facilities. Their substantial scientific, development and corporate expertise is focused on progressing our preclinical programs and accelerating the development of our wholly-owned pipeline with a common objective to bring breakthrough therapies to cancer patients.”
To hire your unveiling curtains, get in contact today:
Email: [email protected]
Telephone: 01635 899551
Or fill in a contact form